Skip to content
PatentBrief
Get alertsTop ↑

Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells

This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.

Granted 2019ActiveExpires 2033Owned by The Ohio State UniversityInvented by Young Bok Lee, Chang Ho Ahn, Deog Joong Kim + 1 more

Original patent title: “Lipid nanoparticle compositions for antisense oligonucleotides delivery”

Plain-English explanation by SahiLast reviewed · November 4, 2026

This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body. Granted to The Ohio State University in 2019 with 35 claims and 3 forward citations, and it is expected to expire in 2033.

Coverage

What does this patent actually cover?

This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.

The gap

What does this patent NOT cover?

  • Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
  • Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
  • Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
  • Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → specify a 'cationic liposome' and a 'net positively-charged core'.
  • Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 10307490
StatusActive
FieldBiotech & Medicine
AssigneeThe Ohio State University
InventorsYoung Bok Lee, Chang Ho Ahn, Deog Joong Kim and 1 other
Filed2013
Granted2019
Expires2033
Claims35
Times cited3
LitigationNone on record
Value · $126K–$403KModest

What made this novel

The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.

The Patent Drawing

Representative patent drawing for Lipid nanoparticle compositions for antisense oligonucleotides delivery (US 10307490)
Representative figure · US 10307490All figures on Google Patents →
Lipid nanoparticle composition…(Primary claim)biotechpharmaceuticalnanotechnologygene editing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Targeted cancer therapies using nanoparticles

02

Gene therapy delivery systems

03

Antisense oligonucleotide (ASO) drug formulations

04

mRNA vaccine delivery (using lipid nanoparticles)

05

Drug delivery systems for inflammatory diseases

Why it matters

The bigger picture

This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.

Filed

May 23, 2013

Granted

June 4, 2019

Market context

Who's building on this

Companies in this space

Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are leaders in developing antisense oligonucleotide (ASO) therapies, often relying on advanced delivery systems. Many biotech startups and major pharmaceutical companies are actively researching and developing targeted nanoparticle delivery systems for various drugs, including gene therapies and oncology treatments. The Ohio State University, as the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, also continues research in this area.

Market impact

This patent contributed to the growing field of targeted drug delivery, enabling more precise administration of therapeutic agents, particularly nucleic acid-based drugs like ASOs. By offering a method to create stable, targeted nanoparticles, it helped pave the way for therapies that can reduce systemic side effects and improve drug efficacy. This approach has become fundamental in the development of modern gene therapies and nanomedicines, influencing how new drugs are formulated and delivered to patients.

Claim 1 — Plain English

What this patent covers

This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claim 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claims 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.

The clever bit

The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.

What it does not cover

  • Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.
  • Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
  • Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
  • Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claims specify a 'cationic liposome' and a 'net positively-charged core'.
  • Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Moderate

Citation count

12/40

Early citations

Claim breadth

20/20

Very broad protection

Recency

10/20

Granted 5–10 years ago

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$126K – $403K

Midpoint $252K · 6.5 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

35 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

27

earlier patents this invention cites as foundations

View prior art →

Cited by later patents

3

later patents that build on this invention

View patents →

Cite this patent

Lee, Y. B., Ahn, C. H., Kim, D. J., & Lee, R. J. (2019). Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells (U.S. Patent No. 10,307,490). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/10307490/lipid-nanoparticle-compositions-for-antisense-oligonucleotides-delivery

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US10307490"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →nanotechnology patents →

Common Questions

Frequently Asked Questions

What does Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells cover?

This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.

Who owns patent US 10307490?

The Ohio State University owns this patent, granted in 2019.

When does this patent expire?

This patent is expected to expire on May 23, 2033, when the invention enters the public domain.

What is patent US 10307490 cited by?

This patent has been cited by 3 later patents that build on its ideas.

What problem does this patent solve?

This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.

What does this patent NOT cover?

Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.

Patent monitoring

Get notified when The Ohio State University files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 4, 2026 · PatentBrief is not a law firm and this is not legal advice.